Laura J Spece1,2, Lucas M Donovan1,2, Matthew F Griffith1,2, Thomas Keller1,2, Laura C Feemster1,2, Nicholas L Smith3,4,5, David H Au1,2. 1. Division of Pulmonary, Critical Care, and Sleep Medicine, and. 2. Health Services Research and Development, and. 3. Cardiovascular Health Research Unit, University of Washington, Seattle, Washington. 4. Epidemiologic Research and Information Center, Department of Veterans Affairs Puget Sound Health Care System, Seattle, Washington; and. 5. Kaiser Permanente Washington Research Institute, Kaiser Permanente Washington, Seattle, Washington.
Abstract
Rationale: Decreasing medication overuse represents an opportunity to avoid harm and costs in the era of value-based purchasing. Studies of inhaled corticosteroids (ICS) overuse in chronic obstructive pulmonary disease (COPD) have examined prevalent use. Understanding initiation of low-value ICS among complex patients with COPD may help shape deadoption efforts. Objectives: Examine ICS initiation among a cohort with low exacerbation risk COPD and test for associations with markers of patient and health system complexity. Methods: Between 2012 and 2016, we identified veterans with COPD from 21 centers. Our primary outcome was first prescription of ICS. We used the care assessment needs (CAN) score to assess patient-level complexity as the primary exposure. We used a time-to-event model with time-varying exposures over 1-year follow-up. We tested for effect modification using selected measures of health system complexity. Results: We identified 8,497 patients with COPD without an indication for ICS and did not have baseline use (inception cohort). Follow-up time was four quarters. Patient complexity by a continuous CAN score was associated with new dispensing of ICS (hazard ratio = 1.17 per 10-unit change; 95% confidence interval = 1.13-1.21). This association demonstrated a dose-response when examining quartiles of CAN score. Markers of health system complexity did not modify the association between patient complexity and first use of low-value ICS.Conclusions: Patient complexity may represent a symptom burden that clinicians are attempting to mitigate by initiating ICS. Lack of effect modification by health system complexity may reflect the paucity of structural support and low prioritization for COPD care.
Rationale: Decreasing medication overuse represents an opportunity to avoid harm and costs in the era of value-based purchasing. Studies of inhaled corticosteroids (ICS) overuse in chronic obstructive pulmonary disease (COPD) have examined prevalent use. Understanding initiation of low-value ICS among complex patients with COPD may help shape deadoption efforts. Objectives: Examine ICS initiation among a cohort with low exacerbation risk COPD and test for associations with markers of patient and health system complexity. Methods: Between 2012 and 2016, we identified veterans with COPD from 21 centers. Our primary outcome was first prescription of ICS. We used the care assessment needs (CAN) score to assess patient-level complexity as the primary exposure. We used a time-to-event model with time-varying exposures over 1-year follow-up. We tested for effect modification using selected measures of health system complexity. Results: We identified 8,497 patients with COPD without an indication for ICS and did not have baseline use (inception cohort). Follow-up time was four quarters. Patient complexity by a continuous CAN score was associated with new dispensing of ICS (hazard ratio = 1.17 per 10-unit change; 95% confidence interval = 1.13-1.21). This association demonstrated a dose-response when examining quartiles of CAN score. Markers of health system complexity did not modify the association between patient complexity and first use of low-value ICS.Conclusions: Patient complexity may represent a symptom burden that clinicians are attempting to mitigate by initiating ICS. Lack of effect modification by health system complexity may reflect the paucity of structural support and low prioritization for COPD care.
Entities:
Keywords:
care quality; chronic obstructive pulmonary disease; inhaled corticosteroids
Authors: Claire O'Hanlon; Christina Huang; Elizabeth Sloss; Rebecca Anhang Price; Peter Hussey; Carrie Farmer; Courtney Gidengil Journal: J Gen Intern Med Date: 2016-07-15 Impact factor: 5.128
Authors: Danijela Korom-Djakovic; Anne Canamucio; Michele Lempa; Elizabeth M Yano; Judith A Long Journal: Am J Med Qual Date: 2014-11-20 Impact factor: 1.852
Authors: Laura J Spece; Eric M Epler; Lucas M Donovan; Matthew F Griffith; Margaret P Collins; Laura C Feemster; David H Au Journal: Ann Am Thorac Soc Date: 2018-09
Authors: C Crim; P M A Calverley; J A Anderson; B Celli; G T Ferguson; C Jenkins; P W Jones; L R Willits; J C Yates; J Vestbo Journal: Eur Respir J Date: 2009-05-14 Impact factor: 16.671
Authors: Raphael J Landovitz; Katherine A Desmond; Jennifer L Gildner; Arleen A Leibowitz Journal: AIDS Patient Care STDS Date: 2016-09 Impact factor: 5.078
Authors: Colin R Cooke; Min J Joo; Stephen M Anderson; Todd A Lee; Edmunds M Udris; Eric Johnson; David H Au Journal: BMC Health Serv Res Date: 2011-02-16 Impact factor: 2.655
Authors: Benjamin R Griffin; Neeru Agarwal; Rachana Amberker; Jeydith A Gutierrez Perez; Kelsi Eichorst; Jennifer Chapin; Amy C Schweitzer; Mariko Hagiwara; Chaorong Wu; Patrick Ten Eyck; Heather Schacht Reisinger; Mary Vaughan-Sarrazin; Ethan F Kuperman; Kevin Glenn; Diana I Jalal Journal: J Hosp Med Date: 2021-10 Impact factor: 2.899
Authors: Andy I Ritchie; Jonathon R Baker; Trisha M Parekh; James P Allinson; Surya P Bhatt; Louise E Donnelly; Gavin C Donaldson Journal: Am J Respir Crit Care Med Date: 2021-07-01 Impact factor: 21.405